This post hoc analysis evaluated albumin/bilirubin (ALBI) score, an objective measure of liver function, in patients receiving pembrolizumab plus best supportive care (BSC) compared with placebo plus BSC in the KEYNOTE-240 study.
This serum proteomic profile provides rigorous evidence that enables understanding of the heterogeneity of IPF and protein alterations that could help in its diagnosis and treatment decisions.
